The RDIF, Russia’s sovereign wealth fund, and India based, Virchow Biotech Private Limited, have today announced a partnership to produce and supply a minimum of 200 million doses of the Russia developed Sputnik V vaccine against COVID-19.
The European Medicines Agency (EMA) has started a rolling review of Sputnik V, a COVID-19 vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology.
Health officials in Azerbaijan have granted approval for a clinical trial to take place in that country combining Russia’s Sputnik V vaccine with the Oxford-AstraZeneca COVID-19 shot in adults 18 years and older.